Patheon IncTSX: PTI

Patheon Special Committee Update Regarding Ontario Securities Commission Proceedings

· Issued by Patheon Inc via CNW

TORONTO, April 14 /CNW/ - The Special Committee of Independent Directors of Patheon Inc. ("Patheon") (TSX:PTI) today provided a further update on the status of its application to the Ontario Securities Commission ("OSC") regarding the legality of the unsolicited offer (the "Offer") by JLL Patheon Holdings LLC ("JLL") to acquire any and all of the issued and outstanding restricted voting shares (the "Restricted Voting Shares") of Patheon not owned by JLL or its affiliates.

The OSC determined last Thursday that JLL's application for exemptive relief could not be considered without a full public hearing, which would not be held until April 30 or May 1. At that hearing, the OSC would also consider the Special Committee's application.

Since last Thursday, the parties have been in discussions with OSC staff regarding the conditions on which JLL would be permitted to proceed with its offer. An OSC pre-hearing has been scheduled for the afternoon of April 15 to consider these conditions. In connection with these proceedings, JLL has offered to: terminate its side deal with a group of Patheon shareholders (the "MOVA Group"), led by Joaquin Viso; make necessary amendments to the Offer and related Offering Circular; and extend the Offer for more than 10 additional days, if the foregoing would be sufficient for the Special Committee's application not to proceed to a full hearing.

The Special Committee has made submissions to the OSC regarding the sufficiency of these actions by JLL, and other conditions that might be imposed if JLL is permitted to proceed with the Offer.

The Special Committee believes that, as a result of these proceedings, JLL will likely be required to extend the Offer beyond the currently scheduled expiry date of April 16.

As previously announced, the Board of Directors of Patheon has determined that, based on the unanimous recommendation of the Special Committee, the Offer is INADEQUATE and advises holders ("Shareholders") of Restricted Voting Shares of Patheon to NOT TENDER their shares to the Offer. BMO Capital Markets has delivered an independent valuation to the Special Committee indicating that, as of February 16, 2009, the fair value of the Restricted Voting Shares is in the range of US4.20 to US$5.00.

The Special Committee believes that Patheon remaining an independent company and executing its business plan can permit Shareholders to realize substantial value, well in excess of the Offer, by retaining their investment in the Company and benefitting from the realization of Patheon's potential.

Shareholders who have tendered their Restricted Voting Shares to the Offer and wish to obtain advice or assistance in withdrawing their shares should contact their broker or Kingsdale Shareholder Services Inc., Patheon's information agent, at the phone number below.

The Special Committee will provide further updates regarding the OSC proceedings or other developments as warranted.

ABOUT PATHEON

Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.

Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.

Patheon's integrated development and manufacturing network of 11 facilities, and 6 development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.

%SEDAR: 00001700E

Patheon Inc on 6ix

Story so far

Earlier from Patheon

Later from Patheon

All Patheon news releases